These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17610528)

  • 1. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.
    Hoetelmans RM; Mariën K; De Pauw M; Hill A; Peeters M; Sekar V; De Doncker P; Woodfall B; Lefebvre E
    Br J Clin Pharmacol; 2007 Nov; 64(5):655-61. PubMed ID: 17610528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
    Sekar VJ; De Pauw M; Mariën K; Peeters M; Lefebvre E; Hoetelmans RM
    Antivir Ther; 2007; 12(4):509-14. PubMed ID: 17668559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.
    Kearney BP; Mathias A; Mittan A; Sayre J; Ebrahimi R; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):278-83. PubMed ID: 17079992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M; Walli RK; Breske A; Kruse G; Stocker H; Banik N; Richter H; Mazur D
    AIDS; 2007 Jun; 21(10):1368-70. PubMed ID: 17545717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
    Sekar VJ; Spinosa-Guzman S; De Paepe E; De Pauw M; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2008 Jan; 48(1):60-5. PubMed ID: 18094220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
    Blum MR; Chittick GE; Begley JA; Zong J
    J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
    Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.
    Ramanathan S; Shen G; Cheng A; Kearney BP
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):274-9. PubMed ID: 17414929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
    Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
    Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
    Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
    Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
    Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.